FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890108371> ?p ?o ?g. }

• W2890108371 abstract "e23021 Background: Early breast cancer is a frequent female disease with different outcomes. New approaches are needed in order to improve its prognosis. MicroRNAs (miRs) are modulators of gene expression and act as oncogenes and function to inhibit tumor suppressors and to promote metastasizing. Monitoring of miRs could be of benefit to the prognosis of EBC patients. Methods: We prospectively collected sera from 133 EBC patients (follow-up 53,25 months) in 3 time points (before I and after surgery II, after therapy III). Patients were stratified into high and low-risk groups according to HR, HER2, Ki-67, grade, LN. For RNA isolation serum was used followed by RT-qPCR and was applied longitudinal multivariate data analysis. Aim of the project was to determine serum expression of miR-155, miR-19a, miR-181b, miR-24 in 3 time points, to find difference in expressions between high and low-risk groups, to find association between miRs and clinical/pathological risk factors and associations in miRs expression and prognosis of EBC. Results: EBC patients significantly over-express miRs in time point I. In time point II the levels of miR-155, miR-181b, miR-24 significantly decreased ( p< 0.05). miR-19a decreased in time point III ( p= 0.00869). Levels of miR-155, miR-19a, miR-181b, miR-24 are significantly more abundant in high-risk in comparison to low-risk patients ( p< 0.05) and decrease upon therapy. The multivariate GEE model revealed that miR-155, miR-24 were predictive of the relapse ( p= 0.025 and 0.041). miR-19a, miR-181b are insignificant with respect to the relapse ( p> 0.05). Triple-negativity, HER2+, grade III, LN+ have no effect on the probability of relapse ( p> 0.05) when miRs are simultaneously taken into an account. The only risk factor that makes the prediction of relapse more precise is Ki-67 > 20% ( p= 0.013 in case of miR-155 and p= 0.023 in case of miR-24). Conclusions: OncomiRs are significantly more abundant in EBC patients at diagnosis and decline after therapy. Differences in miR levels reflect EBC risk groups. The data shows that miR-155 and miR-24 enable monitoring of EBC and predict relapse independently of clinical/pathological risk factors. Combining the miR levels with Ki-67 expression further specifies the relapse probability." @default.
• W2890108371 created "2018-09-27" @default.
• W2890108371 creator A5000010705 @default.
• W2890108371 creator A5010096191 @default.
• W2890108371 creator A5045391525 @default.
• W2890108371 creator A5071571454 @default.
• W2890108371 creator A5081726824 @default.
• W2890108371 date "2017-05-20" @default.
• W2890108371 modified "2023-10-15" @default.
• W2890108371 title "Oncogenic microRNAs to predict relapse in early breast cancer patients." @default.
• W2890108371 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e23021" @default.
• W2890108371 hasPublicationYear "2017" @default.
• W2890108371 type Work @default.
• W2890108371 sameAs 2890108371 @default.
• W2890108371 citedByCount "0" @default.
• W2890108371 crossrefType "journal-article" @default.
• W2890108371 hasAuthorship W2890108371A5000010705 @default.
• W2890108371 hasAuthorship W2890108371A5010096191 @default.
• W2890108371 hasAuthorship W2890108371A5045391525 @default.
• W2890108371 hasAuthorship W2890108371A5071571454 @default.
• W2890108371 hasAuthorship W2890108371A5081726824 @default.
• W2890108371 hasConcept C104317684 @default.
• W2890108371 hasConcept C121608353 @default.
• W2890108371 hasConcept C126322002 @default.
• W2890108371 hasConcept C143998085 @default.
• W2890108371 hasConcept C145059251 @default.
• W2890108371 hasConcept C530470458 @default.
• W2890108371 hasConcept C54355233 @default.
• W2890108371 hasConcept C71924100 @default.
• W2890108371 hasConcept C86803240 @default.
• W2890108371 hasConceptScore W2890108371C104317684 @default.
• W2890108371 hasConceptScore W2890108371C121608353 @default.
• W2890108371 hasConceptScore W2890108371C126322002 @default.
• W2890108371 hasConceptScore W2890108371C143998085 @default.
• W2890108371 hasConceptScore W2890108371C145059251 @default.
• W2890108371 hasConceptScore W2890108371C530470458 @default.
• W2890108371 hasConceptScore W2890108371C54355233 @default.
• W2890108371 hasConceptScore W2890108371C71924100 @default.
• W2890108371 hasConceptScore W2890108371C86803240 @default.
• W2890108371 hasLocation W28901083711 @default.
• W2890108371 hasOpenAccess W2890108371 @default.
• W2890108371 hasPrimaryLocation W28901083711 @default.
• W2890108371 hasRelatedWork W1966325925 @default.
• W2890108371 hasRelatedWork W1967765631 @default.
• W2890108371 hasRelatedWork W2010558732 @default.
• W2890108371 hasRelatedWork W2014661332 @default.
• W2890108371 hasRelatedWork W2026254699 @default.
• W2890108371 hasRelatedWork W2055747658 @default.
• W2890108371 hasRelatedWork W2111632455 @default.
• W2890108371 hasRelatedWork W2160547339 @default.
• W2890108371 hasRelatedWork W2185799008 @default.
• W2890108371 hasRelatedWork W2579976334 @default.
• W2890108371 hasRelatedWork W2598371810 @default.
• W2890108371 hasRelatedWork W2736957744 @default.
• W2890108371 hasRelatedWork W2791608359 @default.
• W2890108371 hasRelatedWork W2897847973 @default.
• W2890108371 hasRelatedWork W2997578720 @default.
• W2890108371 hasRelatedWork W3029306641 @default.
• W2890108371 hasRelatedWork W3038820749 @default.
• W2890108371 hasRelatedWork W3190093674 @default.
• W2890108371 hasRelatedWork W3194687662 @default.
• W2890108371 hasRelatedWork W3208380091 @default.
• W2890108371 isParatext "false" @default.
• W2890108371 isRetracted "false" @default.
• W2890108371 magId "2890108371" @default.
• W2890108371 workType "article" @default.